Company* | Company* | Type/Product Area | Terms/Details (Date) |
| |||
AbNovo Inc.* | Immune Network | Collaboration to develop Immune Network's monoclonal antibody portfolio | AbNovo will be dedicated to developing antibody treatments for viral infections, focusing its initial efforts on the development of hNM01 (7/29) |
Access | Zentaris AG* | Licensing agreement to develop Perifosine to treat cancer | Access gains exclusive rights to develop and market Perifosine in the U.S., Canada and Mexico; Access will make up-front and milestone payments in excess of $18M, pay royalties on net sales of Perifosine and fund all further development (9/18) |
Aerogen Inc. | Discovery | Collaboration to evaluate Discovery's humanized lung surfactant with Aerogen's Aeroneb Professional Nebulizer system for the delivery of aerosolized surfactants to prevent and treat respiratory disease | Financial details were not disclosed (7/29) |
Agilent | Accelrys Inc. | Agreement to develop software designed to assist in drug discovery | Agilent will license Accelrys' Viewer ActiveX Control for 3-D visualization of molecular structures (8/13) |
Alpha | Profile Therapeutics | Agreement for the development of an inhaled alpha-1 proteinase inhibitor product to treat people with emphysema resulting from a genetic deficiency of alpha-1 Pl | Alpha will develop its alpha-1 Pl product as a therapy to be delivered directly to the lung as an aerosolized solution (8/1) |
Ambion Inc.* | Celera Diagnostics (joint venture between the Applied Biosystems Group, NYSE:ABI; and the Celera Genomics Group, NYSE:CRA) | Nonexclusive worldwide licensing agreement for the Armored RNA technology in products and processes for in vitro molecular diagnostics | Financial details were not disclosed (9/6) |
Amersham Bio- | Imaging | Agreement to jointly develop and commercialize a medium-throughput subcellular analysis system called IN Cell Analyzer 1000 | The subcellular analysis system, to be designed for assay development and basic research, is meant to complement the 3000 model (9/23) |
AngioDesign | GenoMed Inc. | Letter of intent to potentially partner in drug discovery projects | Further details were not disclosed (7/31) |
AngioGenetics | Discovery | Agreement to undertake a joint study in which genes identified by AngioGenetics will be validated in vivo by DGI | The focus will be angiogenesis regulation; companies will share any revenues generated as a result of the collaboration (8/1) |
Applied | Myriad | Collaboration to develop technologies and applications for proteomics | Myriad plans to use Applied's 4700 Proteomics Analyzer with TOF/TOF Optics as a platform in its efforts to map the human proteome and to identify drug targets for the prevention and treatment of human disease (8/13) |
Applied | NascaCell GmbH* (Germany) | Nonexclusive, worldwide license agreement for AME's Kauffman patents for directed molecular evolution | NascaCell will use the licensed technology to generate aptamers; financial terms were not disclosed (9/16) |
Aquaartis SA* | TheraSci Ltd.* | Screening agreement to discover lead compounds for neurological disorders | Aquaartis will receive an up-front technology access fee and would receive milestone payments and royalties if com- pounds are discovered and developed (8/22) |
Atrix Laboratories | Immune Network | Agreement providing Immune Network rights to use, for regulatory purposes, certain biological data from studies involving dapsone | Immune Network plans to develop a dapsone product for Alzheimer's disease; Atrix would receive a royalty on sales of any product for which the licensed data are included in a regulatory submission; Immune Network has agreed to pay to Atrix $100,000 annually to maintain the license (8/6) |
Biochemie | Cubist Pharma- | Cubist gets worldwide rights to Biochemie's CAB-175 | Financial terms of the agreement were not disclosed (8/1) |
BioLeads | Elitra Pharma- | Agreement to combine its natural products library with antimicrobial discovery technologies belonging to | The aim is to identify new antibacterial and antifungal drugs; Elitra retains the worldwide marketing rights for all collaboration compounds, and would pay milestone and royalty payments based on successful programs (9/12) |
Biolex Inc.* | Debiopharm SA* (Switzerland) | Collaboration to examine the feasibility of producing an undisclosed recombinant human therapeutic protein in Debiopharm's development portfolio using Biolex's Lemna System | Financial terms were not disclosed (9/12) |
BioReliance | MedImmune Inc. | Laboratory services agreement in which BioReliance will perform a range of assays for certain MedImmune development-stage or commercial products for one year | BioReliance said it is improving its facilities, enhancing capabilities and adding staff to meet the needs of MedImmune (9/18) |
Biovitrum AB* (Sweden) | BioFocus plc | Drug discovery collaboration focused on G protein-coupled receptors | They will jointly identify drug molecules for a number of GPCRs (9/12) |
BioXell SpA* | TaiGen | Exclusive joint collaboration to research and develop new drugs targeting selected members of the G protein- coupled receptor family to treat chronic inflammatory diseases | BioXell will be responsible for receptor target identification and testing candidates in various bioassays; financial terms were not disclosed (9/9) |
British Biotech | GeneSoft Inc.* | Agreement for a broad-based collaboration to discover and develop anti-infective drugs based on British Biotech's bacterial metalloenzyme inhibitors | GeneSoft will make an up-front payment of $4M, and it will pay $1M in a milestone payment, as well as equity worth 3.45% of GeneSoft (8/9) |
Caprion Pharmaceuticals Inc.* (Canada) | IDEC Pharma- | Research collaboration for IDEC to use Caprion's CellCarta, a subcellular proteomics discovery platform, to discover antigens that will be used to develop cancer therapeutics | The collaboration includes a $4M equity investment in Caprion by IDEC, as well as $7M for a technology access fee and research funding; the deal also could include milestone payments and high- single-digit royalties if products result from the collaboration (9/17) |
Celgene Corp. | High Throughput Genomics Inc.* | Agreement to use Celgene's target and drug discovery platform with HTG's Omix Imager system for high-throughput genomic screening | The agreement also includes developing and supplying ArrayPlate kits containing sets of genes associated with disease path- ways targeted by Celgene's drug discovery programs (8/19) |
Cellectis SA* | Artemis Pharma- | Worldwide nonexclusive license agreement under a patent family covering the use of homologous recombination | It allows use of the technology for gene activation and substitution in living organisms (9/19) |
Cetek Corp.* | Essential | Agreement for Essential to use Cetek's high-throughput screening technology to discover antibiotics for itself and its partner, Fujisawa Pharmaceutical Co. Ltd. (Japan) | The companies did not disclose financial terms (8/21) |
Crucell NV | GenVec Inc. | Licensing agreement to supply its PER.C6 cell line to further develop GenVec's lead cardiovascular product candidate, BioBypass angiogen | GenVec received a nonexclusive, commercial license for PER.C6; Crucell will receive an up-front fee and would receive royalties on product sales (8/12) |
Crucell NV | NatImmune A/S* (Denmark) | Research licensing agreement to evaluate the production of mannan-binding lectin on PER.C6 cells | Crucell will receive up-front and annual payments, as well as royalties on net sales of marketed MBL products (9/5) |
Cue | Lynx Therapeutics | Service agreement to study stem cell gene expression | Lynx will receive payments for genomics services it performs on the human stem cell samples it is provided (7/30) |
Curacyte AG* (Germany) | Gambro Dialysatoren GmbH* (Germany) | Agreement under which Gambro will receive an exclusive worldwide sublicense to use Curacyte's protease inhibitors in extracorporeal blood treatment applications | Financial details were not disclosed (9/3) |
Dendreon | Genentech Inc. (NYSE:DNA) | Agreement to develop monoclonal antibodies, small molecules and other products from Dendreon's preclinical Trp-p8 gene platform | Genentech will purchase equity in Dendreon and will provide up-front and milestone payments potentially in excess of $110M (8/13) |
Dendreon | Progenitor Cell Therapy LLC* | Agreement in which Dendreon is outsourcing its cell-processing operations | Progenitor will pay a fee to Dendreon and assume operational, lease and personnel obligations for the facility in Mountain View, Calif. (8/28) |
Devgen NV* | Elegene AG* | Agreement in which Devgen purchased the assets of Elegene, including image acquisition technology and a library of disease models in CNS for pain and Parkinson's and Alzheimer's diseases | Devgen said the purchase fits its disease focus; financial terms were not disclosed (8/8) |
Discovery Partners International | Inspire Pharma- | Collaboration for optimization of lead compounds in Inspire's P2Y12 antagonist program | The collaboration will focus on the optimization of compounds that may be linked to treating cardiovascular disease (8/6) |
DNAPrint genomics Inc. | Exiqon A/S* | Nonexclusive licensing agreement to incorporate Locked Nucleic Acid technollogy into certain pharmacogenomics and forensics tests | The agreement enables DNAPrint to use a specialty modified DNA in the construction of its test kits (8/28) |
Enanta Pharma- | Chiron Corp. | Agreement to develop therapeutics for the hepatitis C virus using Enanta's chemistry expertise | Chiron will grant Enanta a nonexclusive license to some of its HCV patents; Chiron will provide research funding, as well as license fees, potential milestone payments and royalties (9/4) |
Evotec OAI | Microscience | Agreement to form a 50-50 joint venture to develop small-molecule antimicrobial drugs based on targets generated by Microscience's functional genomics platform | The new company, called Vmax, initially will share Microscience's facility in Wokingham (9/4**) |
Genentech Inc. | Serono SA | Raptiva | Agreement gives Serono exclusive rights to market Raptiva in areas outside the U.S., Japan and certain other Asian countries (8/8) |
Genetastix | South Gene | Agreement in which the companies will operate a joint venture, Shanghai IgCon Therapeutics Co. Ltd. | The venture will focus on the development of human therapeutic antibodies against diseases; the deal was signed last November, but the companies just gained the license to start the joint venture this month (9/4) |
Genetic | Perlegen | Exclusive limited-field license to Genetic Technologies' noncoding patents | The license is limited to high-resolution whole-genome analysis; Perlegen will pay cash and securities worth about A$1.6M (US$876,000) (9/9) |
Genmab A/S | Semaia Pharma- | Collaboration to develop new antibody therapeutic products | Genmab will use its fully human antibody technology to create and develop products for up to four cancer disease target molecules discovered and validated by Semaia; parties will share research development and commercialization costs, and will share equally the revenues generated from out- licensing or sales of the antibody products (7/31) |
Genomics Collaborative | Celera Diagnostics (joint venture be- | Agreement to provide clinical materials and data to Celera Diagnostics | The deal is designed to support several of Genomics Collaborative's ongoing programs to detect markers in various unnamed disease states (9/23) |
Genomics Collaborative | LION bioscience | Agreement to creating GCI Clinical, a database of demographic, epidemiological and medical information that complements the Global Repository of Genomics Collaborative Inc. | Further details were not disclosed (9/4) |
Genset SA | Ricerca | Exclusive worldwide license agreement to all therapeutic applications that may result from Genset's patent applications covering the full-length genomic sequences of Chlamydia pneumoniae and Chlamydia trachomatis | Ricerca will own rights to all anti-infective drugs developed in the program; Genset will receive an equity position in Ricerca, along with patent issuance and development milestones and royalties from any drugs developed or co-developed by Ricerca (7/26) |
Gentris Corp.* | Promega Corp.* | Agreement to jointly pursue development of clinical pharmacogenomic products | The purpose of the agreement is to combine the companies' technologies into a robotic liquid handling platform (9/9) |
Gradipore Inc. | Cangene Corp. (Canada; TSE:CNJ) | Exclusive licensing agreement in which Cangene will evaluate Gradipore's platform separation technology, Gradiflow, as an enhancement to its hyperimmune manufacturing process | The agreement specifies up-front and milestone payments by Cangene (9/11) |
Hollis-Eden | Pharmadigm Inc.* | Licensing agreement for certain intellectual property for Hollis-Eden to use in a program of hormonal regulation of genes to treat diseases | Financial terms were not disclosed (8/29) |
Hybridon Inc. | Aegera | Collaboration to develop an antisense drug candidate targeted to down-regulate Aegera's target, XIAP, which has been implicated in the resistance of cancer cells to chemotherapy | Hybridon also licensed to Aegera rights to a portfolio of second-generation antisense chemistries and oral antisense delivery intellectual property owned or licensed by Hybridon; Aegera will pay Hybridon certain up-front and milestone payments that could total about $7.7M, as well as potential royalties (9/17) |
Hybridon Inc. | Micrologix Biotech | Exclusive worldwide rights agreement to a family of patents covering several antisense oligonucleotides targeted to the HPV genome | Hybridon will receive an up-front payment and potential milestone payments totaling up to $5.7M, as well as royalties (9/12) |
Hyseq Pharma- | Celera Diagnostics (joint venture between Applied Bio systems Group, NYSE:ABI; Celera Genomics Group, NYSE:CRA) and the University of California | License agreement for non-exclusive access to a large-scale Hyseq patient sample collection, which contains more than 12,000 DNA samples and accompanying clinical data that are expected to be used to study the molecular genetics of cardiovascular disease | Financial terms were not disclosed (9/9) |
ICOS Corp. | Protarga Inc.* | Agreement to investigate the application of Protarga's Targaceutical vectors to ICOS compounds | Protarga will chemically link fatty acid vectors to ICOS' cancer drug candidates that are based on cell-cycle checkpoints; both companies are investing funds and will mutually own the intellectual property that arises (7/29) |
Isis Pharma- | X-Mine Inc.* | Licensing agreement for X-Mine's products, Opus and X-Miner | Financial details were not disclosed (8/6) |
Luminex Corp. | Celera Diagnostics (joint venture between Applied Biosystems Group, NYSE:ABI; and the Celera Genomics Group, NYSE:CRA) | Licensing and supply agreement for Luminex's patents | Celera Diagnostics gains worldwide, non-exclusive rights to develop and distribute in vitro molecular diagnostic products based on Luminex's xMAP technology; Luminex will receive royalties from the commercialization of Celera Diagnostics' products based on Luminex's technology, as well as revenues from the sale of instruments and xMAP microspheres (8/22) |
MedImmune | Biosite Inc. | Three-year collaboration in which Biosite will use its Omniclonal phage display technology with MedImmune drug targets to generate high-affinity antibodies | Biosite will receive development fees, target maintenance fees, milestone fees and royalties (8/15) |
MedImmune | ViroNovative BV* | Licensing agreement for human metapneumonovirus from ViroNovative | MedImmune will pay ViroNovative $10M up front, fund research and development, and pay milestones and royalties on resulting products (8/15) |
Neugenesis | Novozymes A/S* | Joint research project to develop new methods to produce antibodies | It combines Neugenesis' technology in monoclonal antibodies with Novozymes' expertise in gene technology; the deal includes an option to form a broader partnership (9/20) |
Oxagen Ltd.* | Nordic Bioscience* (Denmark) | Licensing agreement for a Nordic patent covering variants in three genes, each of which represents a diagnostic marker for the detection of predisposition to osteoporosis | Further details were not disclosed (8/29) |
Oxford Glyco- | Actelion Ltd. (Switzerland; SWX:ATLN) | Zavesca | Marketing and distribution agreement for Zavesca in Europe for five years; OGS will manufacture the drug and remain responsible for regulatory activities (7/26) |
PolyBiotech | MediQuest Therapeutics | Agreement in which Poly- Biotech acquired two patents from MediQuest for S-adenosyl methionine regulation and "Methods for Reducing Anti- microbial Resistance" | Further details were not disclosed (8/14) |
Praecis Pharmaceuticals Inc. (PRCS) | Thuris Corp.* | Research collaboration to use Thuris' RapidAging animal models to develop compounds for age-related therapeutic targets in the brain | Thuris will test certain compounds for Praecis and assess their effects against certain age-related pathologies (8/2) |
Pyrosequencing | Bioimics AB* | Agreement granting Pyrosequencing access to intellectual property covering the use of the RNase P gene for identifying clinically relevant bacteria by Bioimics | Pyrosequencing gained an option for an exclusive worldwide license to the RNase P gene for detecting pathogenic organisms; Pyrosequencing will fund a research pro- ject in which Bioimics will use Pyrosequencing's PSQ 96 System to sequence the Endoriboclease P gene in various micro- organisms to validate its use for identifying clinically relevant bacteria (9/3) |
ReNeuron Holdings plc* | Amrad Corp. | Agreement for worldwide rights to a patent from Amrad to use c-Myc and related genes to immortalize neural cells | ReNeuron is working to derive c-Myc immortalized cells to treat Parkinson's disease, Huntington's disease and stroke (9/18**) |
Serenex Inc.* | Chiron Corp. | Collaboration to use Serenex's technology to discover new drug targets and potential off-targets | Chiron will supply Serenex with small-molecule drug-like compounds, and Serenex will use its Proteome Mining and Function Proteome Fractionation technologies to screen the compounds against thousands of potential protein targets simultaneously; Serenex will receive up-front payments for research funding and potential milestone and royalty payments (9/24) |
Targacept | Layton | Agreement in which Targacept acquired Inversine from Layton | Financial details were not disclosed; Targacept believes Inversine holds promise for treating diseases of the central nervous system (8/27) |
Tranzyme | BD Technologies | Alliance to develop products for drug discovery as well as cell and tissue engineering | BD will use Tranzyme's gene delivery and expression technologies, TranzVector and TExT; BD would have the rights to market commercialized products and would pay Tranzyme a fee on the sale of each product; also, BD would provide Tranzyme access to undisclosed intellectual property for Tranzyme's internal drug discovery programs (9/10) |
Variagenics | Renegade Therapeutics* | Worldwide license for its | Variagenics granted Renegade worldwide exclusive rights to all non-allele-specific applications for the research, development and commercialization of small-molecule drugs that target RNA; Variagenics will receive up-front fees, potential milestone payments, reimbursement for patent-related expenses and royalties (7/30) |
| |||
Notes: | |||
# This chart does not include agreements that involve agricultural product development. | |||
* Private companies are indicated with an asterisk. | |||
** Denotes the date the item ran in BioWorld International. | |||
Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | |||
ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Swedish Stock Exchange; TSE = Toronto Stock Exchange |